Search results
Added:
2 weeks ago
Added:
1 month ago
Source:
Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of…
View more
Added:
1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type…
View more
Added:
2 years ago
Join the Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) and Dr Milton Packer (Baylor University Medical Center, US) for a thought-provoking discussion on the present and future of heart failure care at ESC Congress 2023.
In this unique exchange, Dr Packer shares his thoughts on heart failure guidelines and the '2023 Focused Update of the 2021 ESC Guidelines for the…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
A new meta-analysis suggests that the more time an individual's ambulatory blood pressure (ABP) is within the target range proposed by the 2024 European Society of Cardiology (ESC) guidelines, the lower their risk of mortality and cardiovascular events.¹ The findings also highlight that office blood pressure measurements frequently misclassify patients with regard to their actual blood pressure…
View more
Added:
5 months ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure…
View more
Added:
1 year ago
Added:
2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The…
View more
Added:
2 years ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental…
View more
Added:
5 months ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial…
View more